Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eiger Shifts Focus After Phase II Failure In PAH

Executive Summary

Finding no improvement with ubenimex in PAH, Eiger ends development but continues with the drug in lymphedema, plus hepatitis D and post-bariatric hypoglycemia candidates.

Advertisement

Related Content

Finance Watch: Rough US Stock Market Doesn't Stop Biopharma IPOs As Six More Go Public
Finance Watch: Six More IPO Filings As Three More Biopharmas Go Public In The US
Celladon Will Become Rare Disease-Focused Eiger

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC100212

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel